Biotech Sentiment Revives as Samik Pharm Hits Limit Again[K-Bio Pulse] 유진희 2025.10.29 오전 07:39 Protia Ushers in the Era of Immune Management: ‘15 Minutes Is Enough’ 유진희 2025.10.01 오전 07:35 Cellbion Reports Positive Phase 2 Results in Prostate Cancer Therapy 유진희 2025.09.04 오후 06:00 From Corestem to Yuhan: Cellbion Eyes Fast-Track Path for Lu-177-DGUL 유진희 2025.08.27 오전 08:27 DXVX Soars on First License-Out DealNature Cell[K-Bio Pulse] 유진희 2025.07.31 오전 09:00 Wonik Soars on Policy Tailwinds; Y2Solution Gains on Licensing Buzz[K-Bio Pulse] 유진희 2025.06.05 오전 09:10 Biopharma Earnings Drive Undervalued Stocks Higher, L&C Bio Extends Rally[K-Bio Pulse] 유진희 2025.09.09 오전 09:30 Cellbion’s radiotherapy shows 35% ORR, looks to expand Merck ties 유진희 2025.09.05 오전 08:30 Sellbion CEO Kwon Kim: “Maximizing the Power of 177Lu-DGUL Immuno-Oncology Combo” 유진희 2025.07.21 오전 09:30 Cellbion Starts Merck Trial, Targets Global Sales and Licensing 유진희 2025.06.05 오전 10:53 더 보기 로딩중..
phamedaily
phamedaily
![Biotech Sentiment Revives as Samik Pharm Hits Limit Again[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/10/PS25102900301b.jpg)
![DXVX Soars on First License-Out DealNature Cell[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/07/PS25073100552b.jpg)
![Wonik Soars on Policy Tailwinds; Y2Solution Gains on Licensing Buzz[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/06/PS25060500525b.jpg)
![Biopharma Earnings Drive Undervalued Stocks Higher, L&C Bio Extends Rally[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/09/PS25091400101b.jpg)
